![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/20/2884820/0/en/GigaGen-Doses-First-Patient-in-Phase-1-Trial-of-Anti-CTLA-4-Oncology-Drug-Candidate-GIGA-564-in-Advanced-Solid-Tumors.html
https://www.globenewswire.com//news-release/2023/12/12/2794694/0/en/GigaGen-Receives-FDA-Clearance-of-IND-to-Begin-Phase-1-Trial-of-Oncology-Drug-Candidate-GIGA-564-in-Solid-Tumors.html
https://www.globenewswire.com//news-release/2023/10/19/2763125/0/en/GigaGen-Granted-Expansion-of-Contract-with-US-Department-of-Defense-to-Develop-Synthetic-Human-Antibody-Treatments-for-Botulinum-Neurotoxins.html
https://www.globenewswire.com//news-release/2023/09/28/2751133/0/en/GigaGen-Partners-with-the-National-Cancer-Institute-to-Advance-Oncology-Drug-Candidate-GIGA-564.html
https://www.pharmatimes.com/news/gigagens_use_of_2g_unictm_tech_extended_by_proteonic_1480024
https://www.globenewswire.com/news-release/2022/09/15/2517071/0/en/GigaGen-Awarded-Contract-by-U-S-Department-of-Defense-to-Discover-Synthetic-Human-Antibody-Treatments-for-High-Priority-Toxins-and-Pathogens.html
https://www.globenewswire.com/news-release/2022/07/28/2487786/0/en/GigaGen-Publishes-Research-Showcasing-First-Ever-Clinical-GMP-Manufacturing-and-IND-Enabling-Studies-for-its-New-Class-of-Drugs-Recombinant-Polyclonal-Antibodies.html
https://www.globenewswire.com/news-release/2022/05/19/2447167/0/en/GigaGen-Publishes-Research-Demonstrating-the-Potential-of-its-Machine-Learning-Platform-to-Improve-Antibody-Drug-Discovery-and-Development.html
https://www.globenewswire.com/news-release/2021/07/14/2262933/0/en/GigaGen-Publishes-Research-Describing-Novel-Mechanism-of-Action-and-Therapeutic-Potential-of-its-anti-CTLA-4-Drug-Candidate-GIGA-564.html
https://www.globenewswire.com/news-release/2021/04/15/2211106/0/en/GigaGen-Publishes-Research-on-Company-s-Recombinant-Hyperimmunes-in-Nature-Biotechnology.html